BR0313154A - Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b - Google Patents

Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b

Info

Publication number
BR0313154A
BR0313154A BR0313154-8A BR0313154A BR0313154A BR 0313154 A BR0313154 A BR 0313154A BR 0313154 A BR0313154 A BR 0313154A BR 0313154 A BR0313154 A BR 0313154A
Authority
BR
Brazil
Prior art keywords
helper
cell epitopes
lysine
internal
new immunogenic
Prior art date
Application number
BR0313154-8A
Other languages
English (en)
Inventor
David Jackson
Weiguang Zeng
Original Assignee
Council The Queensland Inst Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council The Queensland Inst Of filed Critical Council The Queensland Inst Of
Publication of BR0313154A publication Critical patent/BR0313154A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"NOVOS LIPOPEPTìDEOS IMUNOGêNICOS QUE COMPREENDEM EPITOPOS DE CéLULA T-HELPER E DE CéLULA B". A presente invenção fornece moléculas sintéticas de lipopeptídeo imunogênico que compreendem epitopos de célula T-helper e de células B co-lineares, e métodos para sua produção e uso na geração de respostas imunes primárias e secundárias, e para a vacinação de animais contra antígenos particulares. Mais particularmente, a presente invenção fornece lipopeptídeos altamente solúveis onde a porção de lipídeo é ligada ao grupo de cadeia lateral terminal de uma lisina interna ou análogo de lisina, preferivelmente ao grupo de cadeia lateral terminal de um resíduo de diaminoácido interno. Preferivelmente a lisina interna ou análogo de lisina está posicionada entre o epitopo de T-helper e o epitopo de célula B ou no epitopo de T-helper.
BR0313154-8A 2002-08-12 2003-08-12 Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b BR0313154A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40283802P 2002-08-12 2002-08-12
PCT/AU2003/001018 WO2004014956A1 (en) 2002-08-12 2003-08-12 Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes

Publications (1)

Publication Number Publication Date
BR0313154A true BR0313154A (pt) 2005-08-02

Family

ID=31715903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313154-8A BR0313154A (pt) 2002-08-12 2003-08-12 Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b

Country Status (13)

Country Link
US (2) US7569225B2 (pt)
EP (2) EP2301972A1 (pt)
JP (2) JP4619120B2 (pt)
KR (1) KR101240547B1 (pt)
CN (3) CN1688606A (pt)
AT (1) ATE516308T1 (pt)
AU (1) AU2003250586B2 (pt)
BR (1) BR0313154A (pt)
CA (1) CA2494192C (pt)
DK (1) DK1543039T3 (pt)
ES (1) ES2369664T3 (pt)
HK (1) HK1113163A1 (pt)
WO (1) WO2004014956A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US20100143405A1 (en) * 2004-08-26 2010-06-10 David Charles Jackson Immunotherapy of virus infection
ZA200702329B (en) * 2004-09-10 2008-06-25 Queensland Inst Med Res Truncated LHRH formulations
BRPI0519705A2 (pt) * 2004-12-21 2009-03-10 Vaxinnate Corp composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
JP5227592B2 (ja) * 2005-02-07 2013-07-03 リポテック プロプライエタリー リミテッド アジュバント物質
CN101151280A (zh) * 2005-02-08 2008-03-26 昆士兰医学研究学院委员会 免疫原性分子
WO2006113792A2 (en) 2005-04-19 2006-10-26 Eli Lilly And Company Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
US20070224205A1 (en) 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
CA2660830A1 (en) * 2006-08-14 2008-02-21 Gideon Goldstein Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1
US20090123488A1 (en) * 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
BRPI0604997A (pt) * 2006-11-30 2007-05-22 Fundacao Zerbini vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção
US9289485B2 (en) 2006-11-30 2016-03-22 Luiza Guilherme Guglielmi Therapeutic application of S. pyogenes C-terminal peptide
CA2702154C (en) * 2007-10-09 2017-05-16 The University Of Melbourne A method of transfection and compositions therefor
WO2009059328A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multi- component l2 vaccine for prevention of human papillomavirus infection
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US20110262473A1 (en) * 2008-07-07 2011-10-27 The University Of Melbourne Synthetic vaccine component
CN102256997A (zh) 2008-10-16 2011-11-23 美国辉瑞有限公司 细环病毒分离株和组合物
US8563690B2 (en) * 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
EA201101015A1 (ru) * 2008-12-29 2012-02-28 Лонца Брен Са Способ получения бивалирудина
JP2012523379A (ja) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
TWI409275B (zh) * 2009-06-22 2013-09-21 Nat Health Research Institutes 脂質化腫瘤相關抗原及其免疫治療的組成物及方法
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
US8846388B2 (en) 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
EP2338521A1 (en) * 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
US20130142827A1 (en) * 2010-06-25 2013-06-06 Philadelphia Health & Education Corporation D/B/A Induction of immune response
EP2608802B1 (en) * 2010-08-27 2017-02-22 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
DK2618842T3 (da) 2010-09-22 2019-07-01 Ena Therapeutics Pty Ltd Hidtil ukendt immunstimulerende fremgangsmåde
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
US9328142B2 (en) * 2011-05-25 2016-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of RAS oncoproteins
WO2012168818A1 (en) 2011-06-08 2012-12-13 Ah Usa 42 Llc Infectious clones of torque teno virus
NZ702146A (en) * 2012-06-06 2016-11-25 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
AU2012394394A1 (en) 2012-11-16 2015-06-04 United Biomedical, Inc. Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD)
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
WO2015157189A1 (en) * 2014-04-07 2015-10-15 The Regents Of The University Of California Vaccines and uses thereof
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
JP2018536645A (ja) * 2015-10-28 2018-12-13 味の素株式会社 免疫賦活剤
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
EP3432922B1 (en) 2016-03-21 2020-02-19 South Dakota Board of Regents Orf virus-based platform for vaccine delivery
DE102016005550A1 (de) 2016-05-09 2017-11-09 Emc Microcollections Gmbh Adjuvans zur lnduzierung einer zellulären lmmunantwort
AU2017386682A1 (en) 2016-12-28 2019-07-25 Invvax, Inc. Influenza vaccines
CN107703294B (zh) * 2017-10-12 2019-06-04 华派生物工程集团有限公司 一种用于检测鸡血清中cLHRH抗体效价的ELISA方法
CN109991422A (zh) * 2017-12-29 2019-07-09 复旦大学 基于特异抗血清的棕榈酰化修饰蛋白质的检测方法
CN114174260A (zh) 2019-06-26 2022-03-11 阿克塞利阿肿瘤学私人有限公司 新型分子
CN116348594A (zh) 2020-05-13 2023-06-27 美国卫生和人力服务部 携带一个或多个p基因突变的rsv疫苗
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
TW202233647A (zh) * 2020-11-17 2022-09-01 挪威商霍夫賽思生物保健有限公司 呼吸治療
WO2022170074A1 (en) * 2021-02-05 2022-08-11 Amgen Inc. Enhanced hybridoma generation
CN113009141A (zh) * 2021-02-05 2021-06-22 深圳市国赛生物技术有限公司 化学发光免疫检测试剂盒、用途和检测方法
CN115216451A (zh) 2021-04-16 2022-10-21 硕腾服务有限责任公司 伪狂犬病病毒疫苗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5864008A (en) 1988-03-25 1999-01-26 James; Stephen Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides
DE4119856A1 (de) 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
GB9202219D0 (en) 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
AUPM885194A0 (en) 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6048538A (en) 1997-10-03 2000-04-11 United Biomedical, Inc. Peptides derived from the non-structural proteins of foot and mouth disease virus as diagnostic reagents
US6107021A (en) 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
ATE440960T1 (de) 1999-02-05 2009-09-15 Univ Melbourne T-helferzellen-epitope
CA2404327A1 (en) 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants

Also Published As

Publication number Publication date
JP2006513140A (ja) 2006-04-20
US8367067B2 (en) 2013-02-05
US20070066534A1 (en) 2007-03-22
CA2494192C (en) 2013-01-22
ES2369664T3 (es) 2011-12-02
JP5265511B2 (ja) 2013-08-14
EP1543039A1 (en) 2005-06-22
CN1688606B (zh) 2013-12-25
EP2301972A1 (en) 2011-03-30
WO2004014956A1 (en) 2004-02-19
CN101121754A (zh) 2008-02-13
CN1688606A (zh) 2005-10-26
JP4619120B2 (ja) 2011-01-26
US20100092500A1 (en) 2010-04-15
HK1113163A1 (en) 2008-09-26
US7569225B2 (en) 2009-08-04
DK1543039T3 (da) 2011-10-31
KR20050053608A (ko) 2005-06-08
ATE516308T1 (de) 2011-07-15
AU2003250586B2 (en) 2010-09-23
KR101240547B1 (ko) 2013-03-08
JP2010155832A (ja) 2010-07-15
AU2003250586A1 (en) 2004-02-25
EP1543039A4 (en) 2007-09-19
EP1543039B1 (en) 2011-07-13
CN101121754B (zh) 2012-02-29
CA2494192A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
BR0313154A (pt) Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b
BR0313101A (pt) Novos lipopeptìdeos imunogênicos que compreendem epitopos de linfócitos t-helper e linfócitos t citotóxicos (ctl), e métodos para sua produção e uso
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
BR0114994A (pt) Composição de vacina
ATE510563T1 (de) Künstliche t-helferzell-epitope als immunstimulatoren für synthetische peptidimmunogene
BR0313587A (pt) composições imunoestimuladoras e métodos de estimulação de uma resposta imune
UY27740A1 (es) Nuevos compuestos
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
TR200100936T2 (tr) Terapötik aşılama
DE60238472D1 (de) Abschwächung der immunogenizität von fusionsproteinen
DE60037450D1 (de) Funf-helix protein
CO5280094A1 (es) Un analogo de a o app y una composicion inmunogenica que comprende dicho analogo
MXPA02006029A (es) Lipopeptidos novedosos como agentes antibacterianos.
NO20023829D0 (no) Proteosom influensavaksine
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
BR0209434A (pt) Peptìdeos antimicrobianos e composições
BR9912176A (pt) Epìtopos de célula auxiliar t artificial como estimuladores imunes para imunógenos de peptìdeo sintéticos incluindo peptìdeos de lhrh imunogênicos
MXPA02006030A (es) Lipopeptidos como agentes antibacterianos.
IL154589A0 (en) Membrane penetrating peptides and uses thereof
EA200301223A1 (ru) Лекарственные формы окскарбазепина
EP1557462A3 (en) Transplant acceptance inducing cells of monocytic origin and their preparation and use
BR0306905A (pt) Vacinas de flavivìrus
BR0314554A (pt) ésteres básicos de álcoois graxos e sua aplicação como agentes anti-inflamatórios ou imunomoduladores
AU3042497A (en) Vaccine containing a peroxiredoxin and/or a beta-tubulin
HUP0303977A2 (hu) Eljárás tiszta foszfatidok előállítására és alkalmazásuk kozmetikai, gyógyászati és élelmezési célokra

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.